Bio Plus (099430) Fundamentals 2026 — P/E 15.2x, Revenue Analysis | SniperIQ
Bio Plus (099430) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩216.0B, trading at ₩3510.00 on the KOE. This SniperIQ fundamentals page covers Bio Plus's valuation (P/E 15.2x, P/B 1.2x), profitability (net margin 14.8%), revenue (₩90.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bio Plus's market cap?
Bio Plus (099430) has a market capitalization of approximately ₩216.0B, trading at ₩3510.00 on the KOE. Market cap moves with the live share price.
What is Bio Plus's P/E ratio?
Bio Plus's trailing twelve-month P/E ratio is 15.2x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Bio Plus?
Bio Plus runs a net profit margin of 14.8%, a gross margin of 67.5%, and an operating margin of 14.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bio Plus generate?
Bio Plus reported revenue of ₩90.9B for fiscal year 2025, with net income of ₩15.0B and earnings per share (EPS) of 253. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Bio Plus pay a dividend?
Bio Plus offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Bio Plus financially healthy?
Bio Plus carries a debt-to-equity ratio of 0.36x and a current ratio of 0.94x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bio Plus a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bio Plus (099430) the key facts are: market cap ₩216.0B, P/E 15.2x, revenue ₩90.9B, 52-week range 3510-7920. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Bio Plus's full fundamentals live
Get Bio Plus's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.